Treatment regimen (subgroup analysis with simultaneous ISC-Qu) (initial sample size 318 (106 vs. 212)) Value (test) ISC-Qu group % or mean (± SD) Value control group % or mean (± SD) Valid N test / control group p-value (Chi-Square, Fisher’s or Mann-Whitney- exact test)
Radiation therapy received % (including any combination) 40.0 29.2 105 / 212 0.058
Chemotherapy received % (including any combination) 98.1 94.8 106 / 212 0.232
Chemotherapy: 5-FU / pyrimidines % 97.2 93.4 106 / 212 0.194
Chemotherapy: platin-based drugs % 2.8 5.2 106 / 212 0.400
Chemo- / radiotherapy (ONC) % Only radiotherapy % Only chemotherapy % Chemo- and radiotherapy combined % 100.0 1.9 60.0 38.1 100.0 5.2 70.8 24.1 105 / 212 2 / 11 63 / 150 40 / 51   0.023
Chemotherapy: 1st course duration: mean (SD), (months) 5.2 (3.3) 5.8 (3.1) 104 / 198 0.006
Chemo-/radiotherapy (ONC) total duration: mean, (SD), (months), 8.5 (11.5) 8.7 (12.4) 106 / 204 0.059
ISC-Qu: overall therapy duration: median, (range), (months) 54 (11-141) n/a 106 n/a
Cumulative ISC-Qu dose (mg): mean (SD), [median (range)] 4299 (2349) [4221 (696-10523)] n/a 106 n/a
Estimated mean weekly ISC-Qu dose (mg), mean (SD), [median (range)] 16.2 (6.4) [17 (2-37.7)] n/a 106 n/a
Table 2: Conventional Treatment regimens and Iscador®-Qu dosing.